Latest Information Update: 16 Jul 2016
At a glance
- Originator Tel Aviv University; Yissum Research Development Company
- Class Anti-inflammatories
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation; Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Israel
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Israel
- 22 Mar 2007 Preclinical trials in Inflammation in Israel (unspecified route)